ArticleJournal of immunology (Baltimore, Md. : 1950)2017
Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells.
Article in Journal of immunology (Baltimore, Md. : 1950), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 52 citations in OpenAlex.
- ReducingCancer immunology research · 2018Trial
- Association of baseline immune cell composition with CAR-T cell expansion and survival in Relapsed/Refractory large B-Cell lymphoma.Journal of translational medicine · 2026Article
- Cell therapy manufacturing at full clinical scale: enhancing the quality CAR-T cell therapy starting materials through massively parallel automated microfluidic cell sorting.Lab on a chip · 2026Article
- Effects of CRISPR-Cas9-mediatedMolecular therapy. Methods & clinical development · 2025Article
- CAR-T cell therapy for cancer: current challenges and future directions.Signal transduction and targeted therapy · 2025Review
- Memory matters: T cell phenotype shapes CAR T cell fate.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- T cell phenotype and clonality changes in myeloma patients with short overall survival.JCI insight · 2025Article
- Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Current advances in experimental and computational approaches to enhance CAR T cell manufacturing protocols and improve clinical efficacy.Frontiers in molecular medicine · 2024Review
- Characterization of atypical T cells generated duringFrontiers in immunology · 2024Article
- Light-inducible T cell engagers trigger, tune, and shape the activation of primary T cells.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7.Nature communications · 2023Article
- Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy.Journal for immunotherapy of cancer · 2023Article
- Adapter-Mediated Transduction with Lentiviral Vectors: A Novel Tool for Cell-Type-Specific Gene Transfer.Viruses · 2022Article
- Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins.Frontiers in immunology · 2022Article
- Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.Frontiers in immunology · 2022Review
- Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model.Cancers · 2021Article
- The role of small molecules in cell and gene therapy.RSC medicinal chemistry · 2021Review
- Adoptive Immunotherapy beyond CAR T-Cells.Cancers · 2021Review
- CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
The outcome of therapy with chimeric Ag receptor (CAR)-modified T cells is strongly influenced by the subset origin of the infused T cells. However, because polyclonally activated T cells acquire a largely CD45RO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.